MediWound schedules annual shareholder meeting for May 15

MediWound Ltd., a $142 million market cap company specializing in medicinal chemicals and botanical products, has announced that its 2025 Annual General Meeting of Shareholders (AGM) is set to take place on May 15, 2025, just two days after its scheduled earnings release on May 13. The company, whose shares have declined 27% year-to-date according to InvestingPro data, disclosed the meeting details in a Form 6-K filed with the Securities and Exchange Commission today.

The notice for the AGM and proxy statement, both dated today, will be mailed to shareholders in preparation for the upcoming meeting. Additionally, a proxy card will be distributed to allow shareholders to vote on matters presented at the AGM if they are unable to attend in person.

The company, headquartered in Yavne, Israel, has made the contents of this SEC filing, including exhibits related to the AGM, part of its official records. These documents are incorporated by reference into MediWound's various registration statements filed with the SEC, ensuring that the information is accessible for regulatory purposes and to investors.

As a foreign private issuer, MediWound adheres to the SEC's reporting standards, which include the submission of Form 6-K among other requirements. The company has complied with all necessary regulations by signing and submitting this report through its Chief Financial Officer, Hani Luxenburg.

The announcement of the AGM is a routine corporate governance matter, allowing shareholders to participate in key decisions and oversight of the company's operations. The specific agenda items for the meeting, however, have not been disclosed in the report. Shareholders are advised to review the proxy materials for detailed information regarding the resolutions to be voted on during the meeting.

This news is based on a press release statement and is intended to provide shareholders and the investment community with important corporate governance updates from MediWound Ltd.

In other recent news, Stereotaxis (NYSE:STXS) reported its fourth-quarter 2024 earnings, revealing a revenue of $6.3 million, which was below the anticipated $8.08 million. The company also reported an earnings per share (EPS) of -$0.09, missing the expected -$0.06. Despite these setbacks, Stereotaxis' revenue for the quarter increased by 39% year-over-year. In addition to financial updates, Stereotaxis has been recognized by NVIDIA (NASDAQ:NVDA) for its advancements in AI robotics and has joined the NVIDIA Connect program. This collaboration is expected to enhance Stereotaxis' integration of AI into its robotic systems. The company is also focusing on expanding its catheter portfolio and has plans for new product launches. Looking forward, Stereotaxis anticipates double-digit growth in 2025, as highlighted by the company's strategic plans and future expectations shared by its CEO, David Fischel.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.